Evidence map›Paper›PMID 34409361›Full record

ArticleJAAD international2021

A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB).

Clare L Rogers, Matthew Gibson, Johannes S Kern, Linda K Martin, Susan J Robertson, Benjamin S Daniel, John C Su, Oliver G C Murrell, Grant Feng, Dedee F Murrell

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAAD international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Clare L RogersFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Matthew GibsonFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Johannes S KernDepartment of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Linda K MartinSydney Children's Hospital, Randwick, New South Wales, Australia.
Susan J RobertsonDepartment of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Benjamin S DanielFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
John C SuDepartment of Dermatology, The Royal Children's Hospital, Melbourne, Victoria, Australia.
Oliver G C MurrellPremier Specialists, Dermatology Trials Australia, Kogarah, New South Wales, Australia.
Grant FengFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Dedee F MurrellFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
St George Hospital · AUCancer Trials Australia · AUMonash Health · AUMonash University · AUSydney Children's Hospital · AUUniversity of Melbourne · AUUNSW Sydney · AU

Funding

New Technologies for Patch-Clamp RecordingR01EB002020 · NIBIB · YALE UNIVERSITY · PI SIGWORTH, FREDERICK J · 2003 to 2005
$833k
NIBIB NIH HHS R01 EB002020
6 · The paper itself

Abstract

backgroundThe success of clinical trials in Epidermolysis Bullosa (EB) is dependent upon the availability of a valid and reliable scoring tool that can accurately assess and monitor disease severity. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB) were independently developed and validated against the Birmingham Epidermolysis Bullosa Severity Score but have never been directly compared.

objectiveTo compare the reliability, convergent validity, and discriminant validity of the EBDASI and iscorEB scoring tools.

methodsAn observational cohort study was conducted in 15 patients with EB. Each patient was evaluated using the EBDASI and iscorEB-clinician scoring tools by 6 dermatologists with expertise in EB. Quality of life was assessed using the iscorEB-patient and Quality of Life in EB measures.

resultsThe intraclass correlation coefficients for interrater reliability were 0.942 for the EBDASI and 0.852 for the iscorEB-clinician. The intraclass correlation coefficients for intrarater reliability was 0.99 for both scores. The two tools demonstrated strong convergent validity with each other.

conclusionBoth scoring tools demonstrate excellent reliability. The EBDASI appears to better discriminate between EB types and disease severities.

Indexed as

BEBS, Birmingham Epidermolysis Bullosa Severity Scoreblistering skin diseaseBMD, bone mineral densitometryDDEB, dominant dystrophic epidermolysis bullosadermatologyEBDASI, Epidermolysis Bullosa Disease Activity and Scarring IndexEB, epidermolysis bullosaEBS, epidermolysis bullosa simplexepidermolysis bullosaEpidermolysis Bullosa Disease Activity and Scarring IndexICC, intraclass correlation coefficientInstrument for Scoring Clinical Outcomes of Research for Epidermolysis BullosaiscorEB, Instrument for Scoring Clinical Outcomes of Research for Epidermolysis BullosaJEB, junctional epidermolysis bullosaoutcome measureQOLEB, Quality of Life in Epidermolysis Bullosa scoreQoL, quality of lifeRDEB, recessive dystrophic epidermolysis bullosa

Identifiers

PMID34409361
PMCPMC8362226
OpenAlexW3124345003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.